Prostate, 980-990
benign enlargement of, 982-983, 982b-983b, 983f, 984f
carcinoma of, 989b-990b
colloid carcinoma of, 990
inflammation of, 981-982
normal anatomy and histology of, 980-981, 981f
tumors of, 983-990, 985f, 986f, 987f, 988t
Prostate-specific antigen (PSA), 988
Prostatic hyperplasia, benign or nodular, 982-983, 983b, 983f
Prostatic intraepithelial neoplasia (PIN), 985
high-grade, 986
Prostatitis, 981-982, 982b
acute bacterial, 981
chronic
abacterial, 981
bacterial, 981
granulomatous, 981-982
Prosthetic valves, complications of, 563, 563t
Proteases, 676-677
Protease-activated receptor (PAR), 117-118
Protease-antiprotease imbalance, in emphysema, 676
Proteasomes, 6, 13-14
degradation of, 13f
Protective antigen, in anthrax, 366-367
Proteins
concentrated from serum, 1180t
damage to, cell injury due to, 50
intracellular accumulation of, 63
Protein aggregate myopathies (PAM), 1241t
Protein aggregation, in Alzheimer disease, 1289f
Protein-aggregation diseases, 63
Protein C, 121
Protein-calorie deficiencies, 40
Protein-energy malnutrition (PEM), 433-435, 434b
in developed world, 434
Protein kinase A regulatory subunit 1 (PRKAR1A) gene, in pituitary tumors, 1076t
Protein kinase C (PKC), activation of, 1115-1116
Protein-protein cross-linkages, 49
Protein reabsorption droplets, in proximal renal tubules, 63, 63f
Protein S, 121
Protein tyrosine phosphatase-22 (PTPN22), 1086
Protein tyrosine phosphatase-22 (PTPN22) gene, 1086, 1210
autoimmune diseases and, 216t
in autoimmunity, 215
Proteinopathies, 63, 1252
Proteinuria, asymptomatic, 898
Proteoglycans, 22f
in immediate hypersensitivity, 203
Proteolysis-inducing factor (PIF), 435
Prothrombin gene mutation, and thrombosis, 124
Prothrombin time (PT), 119, 656
Proto-oncogenes, 283-290, 289b-290b, 316-317
Protozoa, 390-395, 390t
sexually transmitted infections, 351t
Protozoal diseases, of CNS, 1279-1280
Proud flesh, 109-110
PRSS1 gene, pancreatitis, 886, 886t
P-selectin, in inflammation, 76, 76t
Pseudo-aneurysm, 501
Pseudo-gout, 1217, 1217f
Pseudo-palisading, in glioblastoma, 1307b-1308b
Pseudoangiomatous stromal hyperplasia, of breast, 1070
Pseudoarthrosis, 1194
Pseudocysts, pancreatic, 889-890, 890b, 890f
Pseudoepitheliomatous hyperplasia, 370b-371b, 1158b
Pseudohermaphroditism, 167
Pseudohypertrophy, 1243
Pseudohypoparathyroidism, 1105
Pseudolaminar necrosis, 1264b
Pseudomonas, in pyogenic osteomyelitis, 1195
Pseudomonas aeruginosa, 369
Pseudomonas infection, 369-370, 369b-370b
Pseudomyxoma peritonei, 273, 1027, 1027f
Pseudophakic bullous keratopathy, 1326
Psoriasis, 209t, 1165, 1165b-1166b, 1166f
Psoriatic arthritis, 1213
Pterygium, 1323
Puerperal infections, pelvic inflammatory disease, 994
Pulmonary atresia, congenital, 537
Pulmonary congestion, 116
Pulmonary edema, in heart failure
left-sided, 529-530
right-sided, 530
Pulmonary embolism (PE), 127
Pulmonary infarction, 697-699, 698b
Pulmonary stenosis, congenital, 537
Pulmonary venous connection, total anomalous, 535
Pupil, 1320f
Pupillary block, 1329
Pure red cell aplasia, 655, 655b
Purkinje network, 525
Purpura(s), 121-122
Henoch-Schönlein, 657
thrombocytopenic
immune
acute, 659
chronic, 658-659
thrombotic, 659-660, 660t
Pus, 73, 91
Pustular psoriasis, 1165b-1166b
Pustule, 1143t
Pyelonephritis, 930-935, 930f, 935b, 1117b-1119b
acute, 931-933, 931b-932b, 932f
chronic, 933-935, 934b, 934f
due to ureteral obstruction, 960-961
xanthogranulomatous, 934b
Pyloric stenosis, 751
Pyogenic bacteria, 91
Pyogenic granulomas, 516
of oral cavity, 728-729, 729f
Pyogenic meningitis, 1272, 1273f
Pyogenic osteomyelitis, 1195-1196
Pyosalpinx, 995b, 995f
Pyrin, in amyloidosis, 259-260
Pyrogens, 99
Pyrosequencing, 176

Q

Q fever, 703t
Quorum sensing, 349

R

Rabies, 1277-1278, 1277b
Race/ethnicity, and breast cancer, 1053
"Rachitic rosary", 441b
Radial scar, of breast, 1049, 1050f
Radial sclerosing lesion, of breast, 1049, 1050f
Radiation, 428
cancer risks from exposures to, 431-432
CNS effects of, 1305
ionizing
biologic effects of, main determinants of, 428-429, 429f, 430f, 430t
injury produced by, 428-432, 429b, 432b
units of, 428
Radiation carcinogenesis, 324-325, 325b
Radiation cystitis, 962
Radiation exposure, and breast cancer, 1053
Radiation pneumonitis, 692-693
Radiation retinopathy, 1336-1337
Radioallergosorbent test (RAST), 679
Radon
as carcinogen, 278t, 432
in indoor air pollution, 409
Ragged red fibers, 1245b, 1245f
RANKL, 1182
in giant cell tumor, 1203
Rapidly progressive glomerulonephritis (RPGN), 898, 912-913, 912t, 913b-914b, 913f
RAS oncogene, 286
Rathke cleft cyst, 1081
Raynaud phenomenon, in systemic sclerosis, 229-230
RB, in osteosarcoma, 1199
RB tumor suppressor gene, 292-293, 293b, 293f
Reactive arthritis, 207t, 1213
Reactive lymphadenitis, 74-75
Reactive nodules, of vocal cords, 739, 739f
Reactive oxygen species (ROS)
in alcohol metabolism, 418
in cell injury, 45f, 47, 48f, 48t
in inflammation, 85
in leukocyte-mediated tissue injury, 82
in phagocytosis, 79-80
in toxicology, 406-407
Real-time PCR, 176
Recanalization, of thrombi, 126, 126f
Receptors, defects in, 143-144
Receptor cross-linking, 16
Receptor-mediated and fluid-phase uptake, 9, 10f
Receptor-mediated endocytosis, 9-10
Receptor-mediated signaling, 17f
Receptor tyrosine kinases (RTKs), 16-17
activity, 300-301
Recombination activating genes (RAG), 190
Red cedar dust, asthma due to, 688t
Red cell aplasia, pure, 655
Red cell count, adult reference range for, 631t
Red cell distribution width, 630, 631t
Red cell enzyme defects, hemolytic disease due to, 634-635, 634f, 635f
Red cell indices, 629-630, 631t
Red cell trauma, hemolytic anemia due to, 644, 644f
"Red neurons", 1252b-1253b
Reduction-oxidation reactions, 47
Reed-Sternberg cells, 606-607, 607b-610b, 608f, 610f
in Hodgkin lymphoma, 255
Reflux nephropathy, 934
Regenerating myofibers, 1237-1238
Regeneration, 100, 100f
cell and tissue, 101-102
liver, 102, 102f
Regenerative medicine, 28-29
Regulated and normal T-cell expressed and secreted (RANTES), 87

www.PTools.ir